Health Condition 1: null- Iron Deficiency Anaemia
Conditions
Interventions
Intervention1: Punarnavadi Mandura along with Dadimadi Ghrita.: PUNARNAVADI MANDURA-Dose â?? 500 mg twice daily
Dosage form - tablet of 250 mg
Packing form-Plastic jar containg 60 tablets
Duration of therapy-12 weeks AND DADIMADI GHRITA -Dose â?? 10 gm twice daily
Dosage form - Ghrita Route of Administration â?? Oral Time of Administration-Twice a day before food Anupana-Lukewarm Water/Milk Packing form-300 gm pet jar Duration of therapy-12 weeks
Intervention2:
Sponsors
Central Council for Research in Ayurvedic Sciences CCRAS
Eligibility
Inclusion criteria
Inclusion criteria: 1) Patients of either sex aged between 15 to 60 years. 2) Patients with iron deficiency anaemia (Hb 8gm-10gm.%), 3) Patients with peripheral blood smear suggestive of Iron deficiency Anaemia 4) Willing and able to participate for 14 weeks.
Exclusion criteria
Exclusion criteria: 1. Patients suffering from Thalassemia major / Aplastic anaemia / Sickle cell anaemia. 2. Patients with evidence of malignancy. 3. Patients suffering from major systemic illness necessitating long term drug treatment (Rheumatoid arthritis, Psycho-Neuro-Endocrinal disorders, Bleeding disorders, etc.) 4. Patients who have a past history of Atrial Fibrillation, Coronary Artery Disease (CAD), Acute Coronary Syndrome, Myocardial Infarction, Stroke or Severe Arrhythmia in the last 6 months. 5. Symptomatic patient with clinical evidence of Heart failure. 6. Patients with poorly controlled Hypertension ( > 160 / 100 mm Hg) 7. Patients suffering from Diabetes Mellitus {B.S. (F) > 250 mg/dl. 8. Patients on prolonged ( > 6 weeks) medication with corticosteroids, antidepressants, anticholinergics, etc. or any other drugs that may have an influence on the outcome of the study. 9. Patients with concurrent serious hepatic disorder (defined as Aspartate Amino Transferase (AST) and / or Alanine Amino Transferase (ALT), Total Bilirubin, Alkaline Phosphatase (ALP) > 2 times upper normal limit), or Renal Disorders (defined as S. Creatinine >1.2mg/dL), Total Serum Cholesterol & / or Serum Triglycerides > 250 mg/dl, Severe Pulmonary Dysfunction (uncontrolled Bronchial Asthma and / or Chronic Obstructive Pulmonary Disease [COPD]). 10. Alcoholics and/or drug abusers. 11. Pregnant / lactating woman 12 H/o hypersensitivity to the trial drug or any of its ingredients. 13 Patients who have completed participation in any other clinical trial during the past six (06) months. 14 Any other condition which the Investigator thinks may jeopardize the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in Hb%Timepoint: At Baseline, 14-28-42-56-70-84 days and at the end of 14 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| _ Symptomatic relief. _ Change in Serum ferritin level. _ Change in Peripheral Blood Smear Picture. Timepoint: Symptomatic relief at Baseline, 14-28-42-56-70-84 days and at the end of 14 weeks. Serum Ferritin and Peripheral Blood Smear at Baseline, day 42 and day 84. | — |
Countries
India
Contacts
Public ContactDr Pradeep Dua
Central Council for Research in Ayurvedic Sciences (CCRAS)
Outcome results
None listed